Martha Valente

Oncología Medica

[Saad Atiq @SaadAtiq24]

Check out our review in @UrologicClinics on adjuvant therapy for muscle invasive bladder cancer! IMvigor011 has defined a new disease state with MRD, and MODERN will provide key insights to further guide our management

https://t.co/ee8GHrXTRX

[Martha Valente @irisbiempica]

@SaadAtiq24 @UrologicClinics @ericjmiller7 @JonAnker1 @IcahnMountSinai @TischCancer @BladderCancerUS Gracias !

[Karamvir Yadav @K_Yadavir]

In BRCA carriers:
Surgery gives maximum prevention.
MRI surveillance offers survival-equivalent outcomes (mid-term).
In resource-variable settings, access to high-quality MRI matters.
Personalise. Don’t generalize.
#MedTwitter #Precisiononcology #BreastCancer @DFCI_BreastOnc @JCO_ASCO @ASCOPost @ASCO @PTarantinoMD @TataMemorialCtr

[Matteo Lambertini, MD PhD @matteolambe]

In healthy #BRCA carriers risk-reducing mastectomy reduces the risk of #BreastCancer without impact on mortality...very different population than our #BRCABCYcollaboration cohort of young patients

@OncoAlert @BlondeauxEva @JCO_ASCO @ASCO #bcsm

Link:
https://t.co/aKfl2nsKZH

[MV Chandrakanth @ChandrakanthMv]

• The entire concept of Confidence Interval captured in a simple doctor–patient conversation
• Wide CI ≠ weak drug
• Often reflects fewer events.

Stats, explained the OPD way 👇
#Oncology #MedEd #ClinicalTrials #StatsSimplified

[Dra. María Natalia Gandur Quiroga @nataliagandur]

🌟🔵 TALAPRO-2: Who Should We Test? Ideal Candidates for Treatment

👨‍⚕️ Presented by Dr. David Lorente
🕐 #GUARDSymposium2025 @OncoAlert

🔵 Test all metastatic prostate cancer patients ➡️ offers prognostic, predictive, and familial risk value
🔵 Test as early as possible (currently standard in mCRPC; implications for mHSPC expected soon)
🔵 HRR gene alterations identify candidates for PARP inhibitors (alone or combined with NHAs)
🔵 Talazoparib + Enzalutamide → the only PARPi + NHA combo showing OS benefit in a phase III trial
🔵 Best results in BRCA-mutated cases, but benefit also observed in other alterations
🔵 Key considerations to find ideal candidates:
  🔹 What is the HRR alteration and its type?
  🔹 What was the prior therapy (ARPi/APA/ENZA/DARO)?
  🔹 What is the patient's general status and disease burden?
  🔹 What are the treatment goals?

@tompowles1 @ProfSyedHussain @MattGalsky @AndreaNecchi
@DrFelixGuerrero @malvarezmaestro @urbano_anido @JaviMolinaC
@Dav_Lorente @vital_hevia @AnaPlatabello1 @dperfen
@DrIacovelli @PBarataMD @Uro_Dominguez @Uro_Oncologist
@RodriguezAntona @cdanicas @drenriquegrande @Ecastromarcos
📌 #ProstateCancer #mHSPC #HRR #PARPi #BRCA #TALAPRO2 #OncoTwitter

[Paolo Tarantino @PTarantinoMD]

Merry ChristmADCs! 🎄 🎯

[@QuePasaEnNL ®️ @LoQuePasaEnNL]

Nuevo León tierra del mejor acero, del mejor concreto, de ingenieros de lo mejor del mundo arruinados por la maldita corrupción en los gobiernos que no pueden hacer un puente vehicular bien hecho porque “así no deja”

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

A beautifully crafted review “Towards targeting the breast cancer immune microenvironment” in @NatureRevCancer by @LoiSher et al not only closes a gap in our up to date understanding of immune microenvironment, but is graphically 🔝
Bravo. Required read.
https://t.co/vu58ecGQ85

[Martha Valente @irisbiempica]

@ElonMuskOde A

[Yakup Ergün @dr_yakupergun]

Renal Cell Carcinoma
https://t.co/HqwdeqDHyz

[Martha Valente @irisbiempica]

@joshuanbarbozam Membership

[Monica Garza @monicagarzag]

Es inaudito y frustrante por decir lo menos, el desenlace en el caso de María Elena Ríos @_ElenaRios.
Una vez más triunfó la injusticia y la impunidad en un caso extremo de violencia contra una mujer.
Qué pésimo mensaje para todas las demás...

[Alejandro Macias @doctormacias]

Entrada de NUEVAS VARIANTES COVID | KP.3 y KP.2🦠 https://t.co/WRS5Hn0UgM vía @YouTube

[Martha Valente @irisbiempica]

@joshuanbarbozam En Youtube 👌

[Yüksel Ürün @DrYukselUrun]

ME: doing my best to stay updated in oncology!

[Oncology Brothers @OncBrothers]

This is the #algorithm we have used during our discussion for #TNBC w/ @oreganruth & @AnnaWeissMD

#bcsm #OncTwitter #MedTwitter #OncEd #BreastCancer @CancerNetwrk

[Yüksel Ürün @DrYukselUrun]

Fracture Risk in Prostate Cancer: Insights from STAMPEDE
🔵 STAMPEDE trial's long-term effects on bone health analyzed using Hospital Episode Statistics (HES) data.
🔵 Key Outcomes:
- 5-year fracture hospitalization rate for advanced disease (M1): 23% and locally advanced (M0): 11%.
- 10-year fracture hospitalization rate for M0 patients: 26%.
- Adding Zoledronic Acid ⬇️fracture risk in M1 patients✅
- No conclusive benefit of ZA in M0 patients.❌
- Docetaxe showed no significant effect on fracture risk.❌
🔵Men with advanced prostate cancer face a high fracture risk. Using bone protection agents like ZA can reduce this risk in metastatic cases.

@Prof_Nick_James @mattsydes @AttardLab
@myESMO @OncoAlert #ESMO23 @OncBrothers @urotoday @Uromigos @urologysummit @Silke_Gillessen @neerajaiims @Tilki_De @TiansterZhang @DrChoueiri @montypal @PGrivasMDPhD @drenriquegrande @ChrisSweens1 @DrRanaMcKay @ravikanesvaran @yekeduz_emre @amerseburger @alshamsi2000 @mishabeltran

[Oncology Brothers @OncBrothers]

#ESMO23 Day2 ⚡️🔥 #CommunityOncology

1. DB04 ⬇️Her2 #bcsm

#NSCLC
2. #ALINA ALK+ @bensolomon1

3. #LIBRETTO431 RET+

4. #PAPILLON Exon20

5. #CM77T ✂️

6. #LITESPARK005 Belzutifan-RCC @DrChoueiri

7. #SPOTLIGHT Cldn18.2 #gism

#OncTwitter #MedTwitter @myESMO #lcsm

1/8

[Enrique Grande @drenriquegrande]

This pic was taken just one ☝🏻 hour before the history of bladder cancer changed. #ESMO23 I’m privileged ☺️
@tompowles1 the Master
@myESMO @OncoAlert @GuardConsortium @urotoday